Skip to content

Clinical study to assess the outcomes of a patient-centred survivorship care plan enhanced with big data and artificial intelligence technologies

Patient-centered survivorship care plan after cancer treatments based on big data and artificial intelligence technologies: a multicenter clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN97617326
Enrollment
160
Registered
2021-03-26
Start date
2021-04-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer and colorectal cancer survivors Cancer Malignant neoplasm of breast

Interventions

The intervention will be implemented via an mHealth App for collecting objective biomarkers (vital signs) and subjective biomarkers (PREMs/PROMs and symptoms of depression) with the support of (embodi
PAM, System Usability Scale
SUS). The study will involve 160 patients (80 survivors of breast cancer and 80 survivors of colon cancer) from four countries (40 each): Belgium, Latvia, Slovenia and Spain. The intervention will be

Sponsors

University of Maribor
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 and =75 years at the moment of recruitment 2. Stable clinical situation, with a life expectancy of more than 2 years according to researcher opinion 3. Ability to understand study instructions, fulfil follow-up visits and sign an informed consent 4. Enough technology literacy that enables the patient to manage with mobile terminals (smartphones, smartphone apps, tablets) 5. Good internet connection in his/her place of residence

Exclusion criteria

Exclusion criteria: 1. Life expectancy, in the physician opinion's, of less than 1 year 2. Diagnosis of dementia or cognitive decline that makes him/her unable to understand study information and/or sign the informed consent 3. Unable for self-management due to dependence on another person for medication compliance, or measuring blood pressure and daily weigh 4. Lacking decision capacity in relation to diet or preparing meals 5. Current participation in another clinical study 6. Patient has no further follow-up possibilities with enrolling investigation during the planned study period (such as anticipated relocation) 7. Patients with major depression or psychiatric medication that hinders their daily activity

Design outcomes

Primary

MeasureTime frame
Perceived self-efficacy measured using the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer) and Strengths Self-Efficacy Scale (SSES) measured prior to the intervention (during recruitment), twice during the intervention (July 2021 and June 2022) and a final measurement at the end of the intervention (December 2022)

Secondary

MeasureTime frame
1. Patient activation measured using the Patient Activation Measure (PAM) measured prior to the intervention (during recruitment), twice during the intervention (July 2021 and June 2022) and a final measurement at the end of the intervention (December 2022) 2. User acceptance measured using System Usability Scale (SUS) measured three times in July 2021(or August), June 2022 and December 2022 3. User experience measured with User Experience Questionnaire (UEQ) measured three times in July 2021(or August), June 2022 and December 2022 4. Inattentive and careless responding measured with Attentive Responding Scale (ASR) and the Directed Questions Scale (DQS) delivered randomly, since the researchers need to classify those participants that might fall into the Inattentive group and indicate why they are inattentive and try to remotivate them

Countries

Belgium, Latvia, Slovenia, Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026